Moderna awarded tender for COVID-19 vaccine in EU, Norway and North Macedonia

Moderna (MRNA) announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union, Norway and North Macedonia. Under the resulting agreement, 17 participating countries can access Moderna’s mRNA COVID-19 vaccine for up to four years. Under the agreement, Moderna can provide its COVID-19 vaccine in several formats, including prefilled syringes. This is the preferred product presentation for healthcare providers as it can decrease the risk of administration errors and save time, which may ultimately improve vaccination campaign efficiency. In September 2024, the European Commission granted marketing authorization for an updated formulation of Moderna’s COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.